Although several studies have demonstrated that combination of an HDAC inhibitor with a MEK inhibitor had synergistic antitumor activity [17–19], the effect and underlying mechanism of this combinational strategy for pancreatic cancer have yet to be explored in detail. This evidence concerns the gene HDAC9 and familial pancreatic carcinoma.